Summary & Overview
HCPCS Q9975: Factor VIII Fc Fusion Protein (Recombinant), per IU
HCPCS Level II code Q9975 designates the per‑IU billing unit for injection of factor VIII Fc fusion protein (recombinant), a long‑acting coagulation factor used in management of hemophilia A. This biologic therapy is clinically important because it enables replacement of deficient factor VIII activity for both on‑demand treatment of bleeding and routine prophylaxis, with implications for dosing, administration site, and payer coverage across the U.S.
Key payers examined include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a national perspective on clinical context, common sites of service for administration, and the aspects of billing that affect utilization and cost reporting. The publication outlines typical service lines associated with injectable biologics and the most relevant coding considerations for claim submission. It also highlights benchmark topics readers can expect: unit‑level pricing behavior, outpatient infusion versus home administration patterns, and payer policy themes that influence prior authorization and medical necessity determinations.
This summary serves as an entry point for clinicians, billing staff, and policy analysts seeking a concise reference on HCPCS Level II code Q9975, its clinical role in hemophilia care, and the payer landscape relevant to national billing and coverage practices.
Billing Code Overview
HCPCS Level II code Q9975 represents an injection of factor VIII Fc fusion protein (recombinant), billed per international unit (IU). The service is a recombinant coagulation factor VIII infusion intended for treatment or prophylaxis of hemophilia A and related bleeding disorders.
Service Type: Therapeutic infusion / injectable biologic
Typical Site of Service: Outpatient infusion center, physician office, hospital outpatient department, or home infusion when administered by a healthcare professional
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult or pediatric individual with hemophilia A who requires replacement therapy using a recombinant factor VIII Fc fusion protein. The patient presents for an infusion in an outpatient infusion center, hospital outpatient clinic, or at home via home health nursing. Indications include routine prophylaxis to prevent spontaneous bleeding, perioperative management for invasive procedures, or treatment of acute bleeding episodes such as hemarthrosis, soft tissue bleeding, or mucosal bleeding. Clinical workflow: pre-visit verification of patient identity and weight, review of recent factor levels and inhibitor status, reconciliation of current factor replacement regimen, calculation of required international units (IU) based on weight and desired factor VIII activity increase, preparation of the product by pharmacy or trained nursing staff, verification of vial concentration and reconstitution per manufacturer instructions, aseptic IV administration of the calculated dose, monitoring for infusion reactions for at least 30–60 minutes, documentation of lot number and IU administered on the medication record and infusion log, and post-infusion instructions for signs of hypersensitivity or thrombosis. Typical sites of service include outpatient infusion centers, hospital outpatient departments, physician offices capable of IV infusion, and home infusion administered by home health nursing or trained caregivers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|